Cell-Cycle Gene Expression in Lovastatin-Induced Medulloblastoma Apoptosis

Canadian Journal of Neurological Sciences

Volumn 30, Issue 4, 2003, Pages 349-357

  Wang, Wei ^a   Macaulay, Robert J B ^b,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DALHOUSIE UNIVERSITY   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVINOLIN; PROTEIN BAX; PROTEIN P16; PROTEIN P27; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DEATH; CELL LINE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; ELECTROPHORESIS; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDULLOBLASTOMA; ONCOGENE C MYC; ONCOGENE RAS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 0347360495     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100003061     Document Type: Article

References (77)

1. Jay V, Becker LE. Brain tumors. Curr Opin Neurol Neurosurg 1990;3:934-942.
2. Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 1994;81:690-698.
3. Rorke LB, Trojanowski JQ, Lee VM, et al. Primitive neuroectodermal tumors of the central nervous system. Brain Pathol 1997;7:765-784.
4. Tomlinson FH, Scheithauer BW, Meyer FB, et al. Medulloblastoma: I. Clinical, diagnostic, and therapeutic overview. J Child Neurol 1992;7:142-155.
5. Nishiyama K, Funakoshi S, Izumoto S, et al. Long-term effects of radiation for medulloblastoma on intellectual and physical development. A case report of monozygotic twins. Cancer 1994;73:2450-2455.
6. Packer RJ. Chemotherapy for medulloblastoma/primitive neuroectodermal tumors of the posterior fossa. Ann Neurol 1990;28:823-828.
7. Tishler DM, Weinberg KI, Sender LS, et al. Multidrug resistance gene expression in pediatric primitive neuroectodermal tumors of the central nervous system. J Neurosurg 1992;76:507-512.
8. Cohen BH, Zweidler P, Goldwein JW, et al. Ototoxic effect of cisplatin in children with brain tumors. Pediatr Neurosurg 1990;16:292-296.
9. Torres CF, Rebsamen S, Silber JH, et al. Surveillance scanning of children with medulloblastoma [see comments]. N Engl J Med 1994;330:892-895.
10. Tobert JA, Hitzenberger G, Kukovetz WR, et al. Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. Atherosclerosis 1982;41:61-65.
11. Keyomarsi K, Sandoval L, Band V, et al. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991;51:3602-3609.
12. Sumi S, Beauchamp RD, Townsend CJ, et al. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 1992;103:982-989.
13. Macaulay RJB, Wang W, Dimitroulakos J, et al. lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro. J Neurooncol 1999;42:1-11.
14. Wang W, Macaulay RJB. Apoptosis of medulloblastoma cells in vitro follows inhibition of farnesylation using manumycin A. Int J Cancer 1999;82:430-434.
15. Bansal N, Houle AG, Melnykovych G. Comparison of dexamethasone and lovastatin (mevinolin) as growth inhibitors in cultures of T-cell derived human acute leukemia lines (CEM). Leuk Res 1989;13:875-882.
16. Perez SD, Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 1994;199:1209-1215.
17. Jones KD, Couldwell WT, Hinton DR, et al. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun 1994;205:1681-1687.
18. Di Matola T, D'Ascoli F, Luongo C, et al. Lovastatin-induced apoptosis in thyroid cells: involvement of cytochrome c and lamin B. Eur J Endocrinol 2001;145:645-650.
19. Feleszko W, Mlynarczuk I, Olszewska D, et al. Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism. Int J Cancer 2002;100:111-118.
20. Larner J, Jane J, Laws E, et al. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 1998;21:579-583.
21. Kim WS, Kim MM, Choi HJ, et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001;19:81-83.
22. Wang W, Macaulay RJB. Mevalonate prevents lovastatin-induced apoptosis in medulloblastoma cell lines. Can J Neurol Sciences 1999;26:305-310.
23. Kohl NE, Conner MW, Gibbs JB, et al. Development of inhibitors of protein farnesylation as potential chemotherapeutic agents. J Cell Biochem (Suppl) 1995;22:145-150.
24. Dimster DD, Schafer WR, Rine J. Control of RAS mRNA level by the mevalonate pathway. Mol Biol Cell 1995;6:59-70.
25. Holstein SA, Wohlford-Lenane CL, Hohl RJ. Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, and RhoB. J Biol Chem 2002;277:10678-10682.
26. Barbacid M. ras genes. Annu Rev Biochem 1987;56:779-827.
27. Bigner SH, Friedman HS, Vogelstein B, et al. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts [published erratum appears in Cancer Res 1990 Jun 15;50(12):3809]. Cancer Res 1990;50:2347-2350.
28. Bigner SH, Friedman HS, Vogelstein B, et al. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts [published erratum appears in Cancer Res 1990 Jun 15;50(12):3809]. Cancer Res 1990;50:2347-2350.
29. Friedman HS, Burger PC, Bigner SH, et al. Phenotypic and genotypic analysis of a human medulloblastoma cell line and transplantable xenograft (D341 Med) demonstrating amplification of c-myc. Am J Pathol 1988;130:472-484.
30. Askew DS, Ashmun RA, Simmons BC, et al. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991;6:1915-1922.
31. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-128.
32. Hermeking H, Eick D. Mediation of c-myc-induced apoptosis by p53. Science 1994;265:2091-2093.
33. Park C, Lee I, Kang WK. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis 2001;22:1727-1731.
34. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 1995;11:211-219.
35. Hall M, Peters G. Genetic alterations of cyclins, cxyclin-dependent kinase, and Cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108.
36. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-1677.
37. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-1163.
38. Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996;271:1861-1864.
39. Poon RY, Toyoshima H, Hunter T. Redistribution of the CDK inhibitor p27 between different cyclin. CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol Biol Cell 1995;6:1197-1213.
40. Rao S, Lowe M, Herliczek TW, et al. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998;17:2393-2402.
41. Gray-Bablin J, Rao S, Keyomarsi K. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res 1997;57:604-609.
42. Giermasz A, Makowski M, Kozlowska E, et al. Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. Int J Cancer 2002;97:746-750.
43. WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem 1998;273:10618-10623.
44. Vidal A, Millard SS, Miller JP, et al. Rho activity can alter the translation of p27 mRNA and is important for RasV12-induced transformation in a manner dependent on p27 status. J Biol Chem 2002;277:16433-16440.
45. Cohen JJ, Duke RC. Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death. J Immunol 1984;132:38-42.
46. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-456.
47. Yonish RE, Resnitzky D, Lotem J, et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345-347.
48. Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51(23 Pt 1):6304-6311.
49. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
50. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-299.
51. Yin C, Knudson CM, Korsmeyer SJ, et al. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997;385:637-640.
52. Grasso L, Mercer WE. Pathways of p53-dependent apoptosis. Vitam Horm 1997;53:139-173.
53. Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 1995;11:199-210.
54. Keles GE, Berger MS, Srinivasan J, et al. Establishment and characterization of four human medulloblastoma-derived cell lines. Oncol Res 1995;7:493-503.
55. Heikkila R, Schwab G, Wickstrom E, et al. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature 1987;328:445-449.
56. Wickstrom EL, Bacon TA, Gonzalez A, et al. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide target against c-myc mRNA. Proc Natl Acad Sci USA 1988;85:1028-1032.
57. Holt JT, Redner RL, Nienhuis AW. An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol Cell Biol 1988;8:963-973.
58. Koster R, Blatt LM, Streubert M, et al. Consensus-interferon and platelet-derived growth factor adversely regulate proliferation and migration of kaposi's sarcoma cells by control of c-myc expression. Am J Pathol 1996;149:1871-1885.
59. Kaptein JS, Lin CKE, Wang CL, et al. Anti-IgM-mediated regulation of c-myc and its possible relationship to apoptosis. J Biol Chem 1996;271:18875-18884.
60. Magee AI, Gutierrez L, McKay IA, et al. Dynamic fatty acylation of p21N-ras. EMBO J 1987;6:3353-3357.
61. Schafer WR, Kim R, Sterne R, et al. Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 1989;245:379-385.
62. Leonard S, Beck L, Sinensky M. Inhibition of isoprenoid biosynthesis and the post-translational modification of pro-p21. J Biol Chem 1990;265:5157-5160.
63. Mangues R, Corral T, Kohl NE, et al. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res 1998;58:1253-1259.
64. Whyte DB, Kirschmeier P, Hockenberry TN, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997;272:14459-14464.
65. Green DR, Mahboubi A, Nishioka W, et al. Promotion and inhibition of activation-induced apoptosis in T-cell hybridomas by oncogenes and related signals. Immunol Rev 1994;142:321-342.
66. Duffy MJ. Cellular oncogenes and suppressor genes as prognostic markers in cancer. Clin Biochem 1993;26:439-447.
67. Dimitroulakos J, Yeger H. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat Med 1996;2:326-333.
68. Agarwal B, Halmos B, Feoktistov AS, et al. Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis 2002;23:521-528.
69. Vitale M, Di Matola T, Rossi G, et al. Prenyltransferase inhibitors induce apoptosis in proliferating thyroid cells through a p53-independent CrmA-sensitive, and caspase-3-like protease-dependent mechanism. Endocrinology 1999;140:698-704.
70. Laufs U, Marra D, Node K, et al. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999;274:21926-21931.
71. Tanaka T, Tatsuno I, Uchida D, et al. Geranylgeranyl-pyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition. J Neurosci 2000;20:2852-2859.
72. Borner MM, Myers CE, Sartor O, et al. Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. Cancer Res 1995;55:2122-2128.
73. Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes [see comments]. Nature 1994;370:220-223.
74. Wagner AJ, Kokontis JM, Hay N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. Genes Dev 1994;8:2817-2830.
75. Guillouf C, Rosselli F, Sjin RT, et al. Role of a mutant p53 protein in apoptosis: characterization of a function independent of transcriptional trans-activation. Int J Oncol 1998;13:107-114.
76. Guillouf C, Rosselli F, Krishnaraju K, et al. p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene 1995;10:2263-2270.
77. Jin Z, Dicker, DT, El-Deiry WS. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 2002;1:82-89.